Skip to main content
ERYTECH Pharma S.A. logo

ERYTECH Pharma S.A. — Investor Relations & Filings

Ticker · ERYP ISIN · FR001400K4B1 LEI · 969500U8ZZCODU8A9374 PA Manufacturing
Open in API
Filings indexed 864 across all filing types
Latest filing 2024-05-15 Earnings Release
Country FR France
Listing PA ERYP

About ERYTECH Pharma S.A.

https://phaxiam.com/

ERYTECH Pharma S.A. is a clinical-stage biopharmaceutical company that develops innovative therapeutics based on its proprietary ERYCAPS platform, which encapsulates drug substances inside red blood cells. This technology is designed to improve the efficacy and safety of treatments by prolonging the drug's circulation time and reducing side effects. The company's primary focus is on developing treatments for severe forms of cancer and orphan diseases. Its lead product candidate, eryaspase, encapsulates the enzyme L-asparaginase to starve cancer cells of essential nutrients, targeting indications such as acute lymphoblastic leukemia and pancreatic cancer.

Recent filings

Filing Released Lang Actions
PHAXIAM provides Business and Financial Update for the First Quarter of 2024
Earnings Release Classification · 1% confidence The document is titled "PHAXIAM provides Business and Financial Update for the First Quarter of 2024". It details business highlights, clinical progress, and financial information specifically for the first quarter (1Q 2024), ending March 31, 2024. This structure—a summary of operational and financial performance for a period shorter than a full year—is characteristic of an Interim/Quarterly Report. Although it mentions a webinar to discuss these results, the core content is the financial and business update itself, making 'Interim / Quarterly Report' (IR) the most appropriate classification over a mere 'Report Publication Announcement' (RPA), especially given the document length (9165 chars) which suggests more than just a brief announcement. It is not a 10-K (Annual Report), not an ER (which is usually just the initial highlights), and not a CT (Transcript). It aligns best with the definition of an Interim / Quarterly Report (IR). Q1 2024
2024-05-15 English
PHAXIAM Therapeutics fait le point sur ses activités et publie l’information financière du premier trimestre 2024
Earnings Release Classification · 1% confidence The document is titled "PHAXIAM Therapeutics fait le point sur ses activités et publie l'information financière du premier trimestre 2024" (PHAXIAM Therapeutics provides an update on its activities and publishes financial information for the first quarter of 2024). It contains key financial highlights (cash position as of March 31, 2024) and significant operational updates regarding clinical trials. This structure—a press release announcing key financial figures for a specific interim period (Q1 2024) along with operational progress—is characteristic of an Earnings Release (ER). Although it contains financial information, it is the initial announcement/summary, not the comprehensive report (which would be an IR or 10-K equivalent). The document also mentions a webinar to discuss these results, further confirming its nature as an Earnings Release. Q1 2024
2024-05-15 French
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 30 avril 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social au 30 avril 2024" (Monthly information relating to the total number of voting rights and shares comprising the share capital as of April 30, 2024). It explicitly references Article 223-16 of the AMF General Regulation (Autorité des Marchés Financiers, the French financial market regulator). The content is a table showing the evolution of the total number of shares and voting rights over several months, culminating in the latest date. This type of mandatory monthly disclosure regarding the total number of shares and voting rights is a standard regulatory filing in France, often related to capital structure changes or major shareholdings, but it does not fit perfectly into the specific categories like DIRS, MRQ, or SHA. Since it is a specific regulatory disclosure that doesn't match the primary definitions (like 10-K, ER, IR), the most appropriate fallback category is Regulatory Filings (RNS), as it is a required regulatory update that doesn't fit the more specific corporate action codes provided.
2024-05-03 French
Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Monthly information related to total number of voting rights and shares composing the share capital – April 30, 2024" and explicitly references Article 223-16 of the French Autorité des Marchés Financiers (AMF) regulation. It provides a table detailing the evolution of the total number of shares and voting rights over several months, culminating in the April 30, 2024 figure. This type of mandatory monthly disclosure regarding the total number of voting rights is a specific regulatory filing requirement, often falling under general regulatory announcements or specific share/voting rights disclosures. Since there is no specific code for 'Monthly Voting Rights Disclosure', and it is a mandatory regulatory update concerning share capital structure and voting rights, it fits best under the general 'Regulatory Filings' (RNS) category, as it is not a dividend announcement (DIV), a major shareholding notification (MRQ, which usually relates to crossing thresholds by external parties), or a capital change announcement (CAP/SHA, which usually involves issuance/buybacks). Given the context of mandatory regulatory reporting on share capital structure, RNS is the most appropriate fallback.
2024-05-03 English
PHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureus
Regulatory Filings Classification · 1% confidence The document is a press release announcing a specific operational milestone: the enrolment of the first patient in a Phase 1 clinical study for a new treatment. It provides key highlights (enrolment, expected results Q3 2024), context on the disease, study design details, and quotes from management and the Principal Investigator. This format—a concise announcement of key operational/clinical progress, often released before a full financial report—is characteristic of an Earnings Release (ER) or a general operational update. Since it is not a full financial report (10-K, IR), a transcript (CT), or a formal regulatory filing announcing a report (RPA), and it focuses on immediate results/updates, it aligns best with the 'Earnings Release' category, which often includes operational milestones alongside preliminary results, or it could be classified as a Regulatory Filing (RNS) if it were less structured. Given the structure focusing on 'announces' and key metrics/timelines, ER is the most appropriate fit among the specific options, as it functions as a major operational update. However, reviewing the definitions, ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document is purely clinical/operational. The closest fit for a non-financial, non-meeting, non-legal, non-management change announcement that is still a formal update is often RNS (Regulatory Filings - general regulatory announcements and fallback). Since it details a clinical trial milestone, which is material information, and doesn't fit other specific categories like LTR (Legal) or MANG (Management change), RNS is the safest fallback for a material operational announcement that isn't a financial report or transcript. Given the options, and recognizing this is a material operational update, RNS (Regulatory Filings) serves as the best general category for significant, non-standard announcements.
2024-04-15 English
PHAXIAM Therapeutics annonce le recrutement du premier patient dans l’étude de phase 1 dans l’endocardite infectieuse causée par le Staphylococcus aureus
Earnings Release Classification · 1% confidence The document is a press release dated April 15, 2024, announcing a specific corporate event: the inclusion of the first patient in a Phase 1 clinical study for infectious endocarditis. It details the study parameters, expected results timeline (Q3 2024), and includes standard forward-looking statements and contact information typical of corporate news releases. This content aligns best with an Earnings Release (ER) which often includes operational and clinical milestones, or potentially a Regulatory Filing (RNS) if it were a mandatory disclosure. However, since it is a focused announcement of operational progress (clinical trial milestone) rather than a comprehensive financial report (10-K, IR) or a general regulatory update (RNS), and given the structure of a press release announcing key operational news, 'Earnings Release' (ER) is the most appropriate fit among the provided options for a significant operational update, even if it's not strictly quarterly earnings. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal financial report (10-K, IR). It is a direct announcement of news, not just an announcement *about* a report (RPA). Q2 2024
2024-04-15 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.